Macrophage targeting drug conjugates with mannose linker

USPTO published patent application US20260091117A1 for novel macrophage targeting drug conjugates. The invention comprises three components: a drug moiety, a mannose moiety for macrophage targeting, and a linker connecting them, which may be a hydrazone group or oxime group. The application is classified under A61K 47/549 and A61P 37/06, indicating therapeutic compositions and immunology/anti-rejection applications. Assignee is P.I.F. Entrepreneurs Ltd. with five named inventors including Alec M. Goldberg and Samuel H. Goldberg.

This is a patent publication providing intellectual property protection for a drug delivery platform, not a regulatory compliance requirement. No immediate action is required from pharmaceutical manufacturers or drug developers unless they are engaged in similar research that may require licensing discussions or freedom-to-operate analysis. The patent grants the assignee exclusive rights to practice the claimed invention upon issuance.